These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12938634)

  • 21. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 22. [Appearance of immune thyroid diseases during beta-interferon therapy of multiple sclerosis].
    Buchinger W; Niederwieser G; Rainer F
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1473. PubMed ID: 10615332
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interferon -beta therapy in multiple sclerosis].
    Satoh J
    Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 26. An open labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Ozuma J
    J Neurosci Nurs; 1996 Apr; 28(2):72. PubMed ID: 8718753
    [No Abstract]   [Full Text] [Related]  

  • 27. Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis.
    Midgard R; Ertresvåg K; Trondsen E; Spigset O
    Neurology; 2005 Jul; 65(1):170-1. PubMed ID: 16009917
    [No Abstract]   [Full Text] [Related]  

  • 28. [Early immunomodulatory treatment of multiple sclerosis: pros and cons].
    Wender M
    Neurol Neurochir Pol; 2003; 37(4):777-82. PubMed ID: 14746238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5623-7, 5630. PubMed ID: 9863300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of early diagnosis of multiple sclerosis.
    Miller JR
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S4-11. PubMed ID: 15253684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
    Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
    Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
    Phillips JT
    Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
    [No Abstract]   [Full Text] [Related]  

  • 34. Interferon beta retinopathy in a patient with multiple sclerosis.
    Post JW; Colleaux K
    Can J Ophthalmol; 2009 Oct; 44(5):e37. PubMed ID: 19798812
    [No Abstract]   [Full Text] [Related]  

  • 35. Erythema elevatum et diutinum, multiple sclerosis and interferon beta.
    Gil M; Chizzolini C; Kaya G; Hauser C
    Dermatology; 2004; 209(1):75-6. PubMed ID: 15237277
    [No Abstract]   [Full Text] [Related]  

  • 36. A distinct subgroup of chronic inflammatory demyelinating polyneuropathy with CNS demyelination and a favorable response to immunotherapy.
    Pineda AA; Ogata K; Osoegawa M; Murai H; Shigeto H; Yoshiura T; Tobimatsu S; Kira J
    J Neurol Sci; 2007 Apr; 255(1-2):1-6. PubMed ID: 17306302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rationale for an early treatment of multiple sclerosis].
    Comi G; Martino G
    Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Subclinical lesions of peripheral nervous system in multiple sclerosis patients].
    Pogorzelski R; Baniukiewicz E; Drozdowski W
    Neurol Neurochir Pol; 2004; 38(4):257-64. PubMed ID: 15383952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases.
    Batay F; Al-Mefty O
    Acta Neurochir (Wien); 2002 Apr; 144(4):365-8. PubMed ID: 12021883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
    Kocer B; Nazliel B; Oztas M; Batur HZ
    Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.